MedPacto Presents New Drug Substance for Bone Disease at American College of Rheumatology Poster Session

"New Drug for Bone Disease Treatment Shows Effectiveness in Arthritis Therapy"

MedPacto announced on the 15th that it presented preclinical data of the new drug candidate for bone disease treatment, 'MP2021,' in a poster session at the American College of Rheumatology 2023 (ACR 2023).

[Photo by MedPacto]

MP2021 is a novel drug candidate targeting bone diseases and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoporosis. It is the next pipeline following MedPacto's anticancer new drug 'Bactosertib.'

MP2021 is a drug that targets a protein playing a key role in the formation and resorption of multinucleated osteoclasts. Unlike existing treatments that focus on suppressing inflammation, MP2021 fundamentally inhibits the formation of multinucleated osteoclasts that destroy bones, thereby preventing bone loss along with its anti-inflammatory effects. Osteoclasts in human bone marrow differentiate to form multinucleated osteoclasts, which erode bones and act as major factors in bone diseases such as rheumatoid arthritis and osteoporosis.

In the preclinical data disclosed this time, MP2021 was confirmed to suppress inflammation in a collagen-induced arthritis (CIA) mouse model. In the experimental group treated with MP2021, cartilage damage, bone erosion, and the expression of inflammation-related genes were significantly reduced compared to the control group. Additionally, it significantly inhibited inflammatory bone destruction by blocking the overactivation of osteoclasts caused by inflammation.

MedPacto plans to develop MP2021 as a treatment for autoimmune diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, as well as bone diseases like osteoporosis, conduct related clinical trials, and pursue joint development and technology transfer in the future.

A MedPacto official stated, "This study demonstrated the potential for MP2021 to be developed as a new effective treatment for various bone and joint diseases, including rheumatoid arthritis," adding, "We are considering joint development with global pharmaceutical companies and are pursuing technology transfer going forward."

Meanwhile, ACR is one of the largest rheumatology conferences worldwide and was held this year from the 10th to the 15th (local time) in San Diego, USA.

This content was produced with the assistance of AI translation services.